| Rebecca Lynn Reed, CPNP-PC | |
|
1177 Providence Highway, Norwood, MA 02062 | |
| (781) 329-1400 | |
| Not Available |
| Full Name | Rebecca Lynn Reed |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 1177 Providence Highway, Norwood, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407331853 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | RN2273188 (Massachusetts) | Secondary |
| 363LP0200X | Nurse Practitioner - Pediatrics | RN2273188 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca Lynn Reed, CPNP-PC 2570 Acushnet Ave, New Bedford, MA 02745-3032 Ph: (508) 971-9522 | Rebecca Lynn Reed, CPNP-PC 1177 Providence Highway, Norwood, MA 02062 Ph: (781) 329-1400 |
News Archive
Two separate bills have been introduced to address this health law issue, which inadvertently would make 3 million middle-income early retirees eligible for Medicaid because Social Security benefits would not be factored into their income. The fix could save $13 billion. However, it's not clear if either measure will move forward.
Punyamurtula S. Kishore MD, MPH, FASAM, of Preventive Medicine Associates, Inc. (PMAI), the largest outpatient substance dependence provider in Massachusetts, announced today his 37 clinical locations will be offering new addiction treatment options through the use of VIVITROL (naltrexone for extended-release injectable suspension), which was approved on Tuesday, October 12, 2010 by the U.S. Food and Drug Administration (FDA) for the prevention of relapse to opioid dependence.
Mary Ann Liebert, Inc. announces the launch of Games for Health: Research, Development, and Clinical Applications (G4H), a new, peer-reviewed journal dedicated to the development, use, and applications of game technology for improving physical and mental health and well-being.
Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.
› Verified 9 days ago